Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 6/2021

01-06-2021 | Sleeve Gastrectomy | Brief Communication

C Peptide Fails to Improve the Utility of the DiaRem Algorithm in Predicting Remission of Type II Diabetes After Bariatric Surgery

Authors: Richard L. Seip, Tara McLaughlin, Madison O’Brien, Ilene Staff, Aashish Samat, Devika Umashanker, Darren Tishler, Pavlos K. Papasavas

Published in: Obesity Surgery | Issue 6/2021

Login to get access

Abstract

We evaluated the utility of C peptide as an addition to the DiaRem score for predicting type 2 diabetes (T2D) remission 1 year after bariatric surgery in 175 patients. DiaRem score was significantly correlated with C peptide (r = − .43; p < .001). Both DiaRem and C peptide were significant predictors of remission of T2D (OR (95% CI) = .81 (.75–.86); p < 0001 and OR (95% CI) = 1.35 (1.15–1.60); p < .001, respectively). ROC analysis indicated that DiaRem was a significantly stronger predictor than C peptide (p < .001). Hierarchical regression indicated that C peptide failed to significantly improve the prediction of diabetes remission after accounting for DiaRem (OR (95% CI) = 1.079 (.87–1.26); p = .406). This study does not support the inclusion of C peptide in the DiaRem algorithm.
Literature
1.
Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol. Jan 2014;2(1):38–45.CrossRef
2.
Aminian A, Brethauer SA, Kashyap SR, et al. DiaRem score: external validation. Lancet Diabetes Endocrinol. 2014;2:12–3.CrossRef
3.
Craig Wood G, Horwitz D, Still CD, et al. Performance of the DiaRem score for predicting diabetes remission in two health systems following bariatric surgery procedures in Hispanic and non-Hispanic white patients. Obes Surg. 2018;28:61–8.CrossRef
4.
Adams TD, Arterburn DE, Nathan DM, et al. Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care. 2016;39:912–23.CrossRef
5.
Park JY, Kim YJ. Prediction of diabetes remission in morbidly obese patients after Roux-en-Y gastric bypass. Obes Surg. 2016;26:749–56.CrossRef
6.
Kao PC, Taylor RL, Heser DW. C-peptide immunochemiluminometric assay developed from two seemingly identical polyclonal antisera. Ann Clin Lab Sci. 1992;22:307–16.PubMed
7.
Lee WJ, Chong K, Chen SC, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg. 2016;26:2418–24.CrossRef
8.
Pucci A, Tymoszuk U, Cheung WH, et al. Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabet Med. 2018;35:360–7.CrossRef
9.
Aron-Wisnewsky J, Sokolovska N, Yuejun L, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia. 2020;60:892–1902.
10.
Kam H, Tu Y, Pan J, et al. Comparison of four risk prediction models for diabetes remission after Roux-en-Y gastric bypass surgery in obese Chinese patients with type 2 diabetes mellitus. Obes Surg. 2020;30(6):2147–57.CrossRef
11.
Khorgami Z, Zhang C, Messiah SE, et al. Predictors of postoperative aftercare attrition among gastric bypass patients. Bariatr Surg Pract P. 2015;10(2):79–83.
12.
Kedestig J, Stenberg E. Loss to follow-up after laparoscopic gastric bypass surgery – a post hoc analysis of a randomized clinical trial. SOARD. 2019;15:880–6.
Metadata
Title
C Peptide Fails to Improve the Utility of the DiaRem Algorithm in Predicting Remission of Type II Diabetes After Bariatric Surgery
Authors
Richard L. Seip
Tara McLaughlin
Madison O’Brien
Ilene Staff
Aashish Samat
Devika Umashanker
Darren Tishler
Pavlos K. Papasavas
Publication date
01-06-2021
Publisher
Springer US
Published in
Obesity Surgery / Issue 6/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05227-x

Other articles of this Issue 6/2021

Obesity Surgery 6/2021 Go to the issue

Original Contributions

Long-term Emergency Department Visits and Readmissions After Laparoscopic Roux-en-Y Gastric Bypass: a Systematic Review

Correction

Correction to: One Anastomosis Gastric Bypass with a Biliopancreatic Limb of 150 cm: Weight Loss, Nutritional Outcomes, Endoscopic Results, and Quality of Life at 8-Year Follow-Up

Letter to the Editor

Metabolic/Bariatric Surgery during COVID-19

Original Contributions

Impact of COVID-19 Lockdown on Short-Term Results After Laparoscopic Sleeve Gastrectomy

Original Contributions

Implications of Technical Factors in Development of Early Sleeve Stenosis After Laparoscopic Sleeve Gastrectomy: an Analysis Using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program Database

Multimedia Article

Missing Jejunal Perforation During Small Bowel Measurement in Patient Operated by Laparoscopic One-Anastomosis Gastric Bypass